Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis

Oliver Kepp, Peng Liu, Liwei Zhao, Isabelle Plo, Guido Kroemer

    Research output: Contribution to journalArticlepeer-review

    18 Citations (Scopus)

    Abstract

    Increased exposure of calreticulin (CALR) on malignant cells is associated with therapy-relevant adaptive immune responses and superior therapeutic outcome in solid tumors and haemato-oncological diseases, because surface-exposed CALR acts as an ‘eat-me’ signal facilitating the phagocytosis of stressed and dying cancer cells by immature dendritic cells, thus favoring antitumor immune responses. On the contrary, mutations of the CALR gene that cause the omission of the C-terminal KDEL endoplasmic reticulum retention motif from CALR protein, resulting in its secretion from cells, act as oncogenic drivers in myeloproliferative neoplasms via the autocrine activation of the thrombopoietin receptor. We recently showed that soluble CALR inhibited the phagocytosis of cancer cells by dendritic cells, thus dampening anticancer immune responses. Furthermore, systemic elevations of soluble CALR that is secreted from tumors or that is artificially supplied by injection of the recombinant protein decreased the efficacy of immunotherapy. Thus, depending on its location, CALR can have immunostimulatory or immunosuppressive functions.

    Original languageEnglish
    Article number1792037
    JournalOncoImmunology
    Volume9
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 2020

    Keywords

    • Immunosuppression
    • calreticulin secretion
    • immune checkpoint blockade

    Cite this